| Nov 8 |
Amgen, AstraZeneca post Phase 3 win for nasal polyps therapy
|
| Nov 8 |
AstraZeneca’s China-Fueled Plunge May Be Difficult to Shake Off
|
| Nov 8 |
Tezspire succeeds in chronic rhinosinusitis; Gilead writes down Trodelvy value
|
| Nov 7 |
Astrazeneca (AZN) Surpasses Market Returns: Some Facts Worth Knowing
|
| Nov 7 |
Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus
|
| Nov 7 |
AstraZeneca: Contrarian Buy After The China Challenge (Rating Upgrade)
|
| Nov 7 |
Unveiling Astrazeneca (AZN) Q3 Outlook: Wall Street Estimates for Key Metrics
|
| Nov 7 |
AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024
|
| Nov 7 |
Q3 2024 Ionis Pharmaceuticals Inc Earnings Call
|
| Nov 6 |
Buy, Sell, or Hold AstraZeneca Stock? Key Tips Ahead of Q3 Earnings
|
